Compare FA & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | AGIO |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 2013 |
| Metric | FA | AGIO |
|---|---|---|
| Price | $12.10 | $27.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $15.50 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 1.5M | 791.9K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,574,389,000.00 | $43,011,000.00 |
| Revenue This Year | $8.11 | $75.68 |
| Revenue Next Year | $7.34 | $167.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $22.24 |
| 52 Week High | $19.01 | $46.00 |
| Indicator | FA | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 42.16 |
| Support Level | $8.82 | $26.40 |
| Resistance Level | $14.56 | $29.49 |
| Average True Range (ATR) | 0.65 | 1.18 |
| MACD | 0.40 | -0.19 |
| Stochastic Oscillator | 82.45 | 14.64 |
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.